BiomimX develops human beating organ-on-chips as innovative platforms to create preclinical models with real tissue functionality to test safety and benefit of drugs in a more reliable fashion. BiomimX addresses the urgent need of Pharma companies for advanced in vitro models of human organs and diseases, with the final aim to lead to a more efficient, faster and less expensive launch of drugs into market. This need is also driven by a paradigm shift towards the 3R principles, forcing Pharma to reduce animal testing. Thanks to its core uBeat technology, BiomimX engineers 3D human microtissues featuring an unprecedented resemblance to native organs and disease, addressing two of the main problems faced today by Pharma companies. Drug safety: Cardiovascular toxicity is one of the leading causes of drug attrition, responsible for 45% of drugs withdrawal from the market. Reliable in vitro tools to predict cardiotoxicity in early pre-clinical phases are not yet available. BiomimX has developed uHeart, a 3D miniaturized in vitro model of a human beating heart enabling for the first time for a real-time detection of drug-induced cardiotoxicity. Drug benefit: BiomimX also focuses in paradigmatic pathologies where treatments are absent due to a complete lack in preclinical models. Among them, Osteoarthritis (OA) has high incidence but no treatment available. BiomimX has developed uKnee, the first in vitro model of human OA cartilage.